• If you are wondering whether Progyny's current share price reflects its true worth, this article walks through what the numbers are really saying about the stock.
• After closing at US$21.65, the shares have seen recent pressure, with returns of a 10.6% decline over 7 days, 19.8% decline over 30 days, 15.9% decline year to date, 3.1% decline over 1 year, 32.9% decline over 3 years, and 57.0% decline over 5 years.
• These moves come against a backdrop of ongoing interest in fertility benefits and employer sponsored health solutions. This keeps Progyny on the radar for investors who follow the healthcare and benefits space. Recent coverage has focused on how specialized benefit platforms fit into broader trends in employee wellness and cost management, which can frame how the market views Progyny's role and pricing power.
• On our checks, Progyny scores 4 out of 6 for potential undervaluation, giving it a 4/6 valuation score. Next, we will break down what that means across different valuation methods before finishing with an approach that can help you interpret these numbers in a more complete way.

Approach 1: Progyny Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects a company’s future cash flows and then discounts them back to what they might be worth in today’s dollars. It is essentially asking what you would pay now for all the cash Progyny could generate for shareholders in the future.

For Progyny, the latest twelve month free cash flow is about $199.8 million. Based on analyst inputs for the next few years and then further extrapolations by Simply Wall St, projected free cash flow reaches $259.6 million in 2030, with a series of annual forecasts between 2026 and 2035 built into the 2 Stage Free Cash Flow to Equity model.

When those cash flows are discounted back, the model arrives at an estimated intrinsic value of around $76.42 per share. Compared with the recent share price of $21.65, this particular DCF suggests Progyny trades at a large implied discount, with the model indicating the stock is 71.7% undervalued on these assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Progyny is undervalued by 71.7%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.

Approach 2: Progyny Price vs Earnings

The P/E ratio is a common way to look at profitable companies because it connects what you pay per share with the earnings the business is already producing. In general, higher growth expectations and lower perceived risk can support a higher “normal” P/E, while slower growth or higher risk usually point to a lower one.

Progyny currently trades on a P/E of 33.0x. That sits above the broader Healthcare industry average of 22.8x, but below the peer group average of 47.6x. To get a more tailored view, Simply Wall St calculates a proprietary “Fair Ratio” for Progyny of 22.2x. This is the P/E that might be expected given factors such as its earnings growth profile, industry, profit margins, market cap and company specific risks.

Because the Fair Ratio is built around Progyny’s own fundamentals rather than a simple comparison set, it can give a more company specific anchor than just looking at industry or peer averages. Set against that Fair Ratio of 22.2x, the current P/E of 33.0x suggests the shares are trading at a premium on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 22 top founder-led companies.

Upgrade Your Decision Making: Choose your Progyny Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple tool on Simply Wall St’s Community page that lets you attach your own story about Progyny to specific forecasts for revenue, earnings and margins. You can then link that forecast to a Fair Value, and compare it with the current share price so you can decide how to act. Each Narrative updates automatically when new news or earnings arrive and reflects different viewpoints, such as a more optimistic Progyny Narrative with a Fair Value around US$33.00 and a more cautious one around US$26.00, or analyst targets that range from US$21.00 up to US$32.00. This way, you can quickly see which story, and which Fair Value, best matches how you see the company.

Do you think there's more to the story for Progyny? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.